FDA Warning on Xylazine: Mitigating Human Risk | by: Sumeet Singh, Founder & Chairman | Article Posted: November 6, 2023 | The U.S. Food and Drug Administration (FDA) has issued a warning regarding mitigating risks from human Xylazine exposure. FDA has not...
Two separate PBMs recently issued audits to an independent pharmacy because it was determined that the pharmacy was sourcing diverted test strips from an NABP DDA (fka VAWD®) Accredited facility.
Optum Rx’s requirement for their network pharmacies to only purchase prescription drug and diabetic testing supplies from Accredited wholesalers has caused significant disruption and controversy since its implementation in August 2016. The requirement spurred two separate lawsuits. The second, which continues in full force, has a recent amended complaint – and Pharma Solutions has unique insight into the lawsuit’s developments.
Top 5 Most Common PSL Findings Overview: NABP DDA accreditation consists of three main parts, which are the application review, policy &...
Omnicare, a leading provider of closed-door pharmacy services, agreed to pay more than a $15 million civil penalty for allowing opioids and other controlled substances to be dispensed without a valid prescription. The fine zeroes in on a common issue amongst pharmacies – discerning between office stock and shipping pursuant to a prescription.
This week, we explore how to legally and ethically navigate supplying products during the pandemic. It is the wild west in the hospital supply business – from illegal import practices and price-gouging to ingenious manufacturing and extra hours.
This week, we provide more information on the short-term and long-term solutions that India and the United States have taken to protect their drug supply chain.
